AbbVie Inc. $ABBV Shares Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI lifted its position in AbbVie Inc. (NYSE:ABBV) by 39.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 154,684 shares of the company’s stock after buying an additional 44,068 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in AbbVie were worth $28,713,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Hedeker Wealth LLC increased its position in shares of AbbVie by 273.2% in the second quarter. Hedeker Wealth LLC now owns 3,669 shares of the company’s stock valued at $681,000 after buying an additional 2,686 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in AbbVie by 1.1% during the second quarter. Avantax Advisory Services Inc. now owns 222,399 shares of the company’s stock worth $41,282,000 after buying an additional 2,458 shares during the period. MJP Associates Inc. ADV raised its stake in AbbVie by 3.6% during the second quarter. MJP Associates Inc. ADV now owns 7,051 shares of the company’s stock worth $1,309,000 after purchasing an additional 245 shares during the period. Cetera Investment Advisers raised its holdings in shares of AbbVie by 4.4% in the 2nd quarter. Cetera Investment Advisers now owns 681,311 shares of the company’s stock worth $126,465,000 after purchasing an additional 28,786 shares during the period. Finally, Compass Financial Services Inc increased its position in shares of AbbVie by 6.6% in the second quarter. Compass Financial Services Inc now owns 1,210 shares of the company’s stock worth $225,000 after acquiring an additional 75 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ABBV shares. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. UBS Group upped their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Piper Sandler reissued an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Citigroup dropped their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Finally, Morgan Stanley upped their price target on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $232.43 on Friday. The stock has a market capitalization of $410.79 billion, a price-to-earnings ratio of 110.68, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The business’s fifty day moving average price is $224.89 and its two-hundred day moving average price is $203.98. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the business posted $3.00 earnings per share. The company’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.